Evidence map›Paper›PMID 38932805›Full record

ArticleJournal of diabetes and metabolic disorders2024

Protocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed lOoP In chiLdren and yOuth with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trial.

Alisa Boucsein, Yongwen Zhou, Jillian J Haszard, Craig A Jefferies, Esko J Wiltshire, Sara E Styles, Hamish R Crocket, Barbara C Galland, Maheen Pasha, Goran Petrovski and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alisa BoucseinDepartment of Women's and Children's Health, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-6266-8802
Yongwen ZhouDepartment of Women's and Children's Health, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-0558-6712
Jillian J HaszardBiostatistics Centre, University of Otago, Dunedin, New Zealand.ORCID 0000-0001-6312-7795
Craig A JefferiesStarship Child Health, Te Whatu Ora Te Toka Tumai Auckland, Auckland, New Zealand.ORCID 0000-0002-0541-6094
Esko J WiltshireDepartment of Paediatrics and Child Health, University of Otago Wellington, Wellington, New Zealand.ORCID 0000-0002-8962-2708
Sara E StylesDepartment of Human Nutrition, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-8358-881X
Hamish R CrocketTe Huatakia Waiora School of Health, University of Waikato, Hamilton, New Zealand.ORCID 0000-0002-7134-6776
Barbara C GallandDepartment of Women's and Children's Health, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-2376-3575
Maheen PashaSidra Medicine, Doha, Qatar.
Goran PetrovskiSidra Medicine, Doha, Qatar.ORCID 0000-0002-8622-2186
Ryan G PaulTe Huatakia Waiora School of Health, University of Waikato, Hamilton, New Zealand.
Martin I de BockDepartment of Paediatrics, University of Otago, Christchurch, New Zealand.ORCID 0000-0003-0454-6679
Benjamin J WheelerDepartment of Women's and Children's Health, University of Otago, Dunedin, New Zealand.ORCID 0000-0003-3348-5238

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Advanced hybrid closed loop (AHCL) systems have the potential to improve glycemia and reduce burden for people with type 1 diabetes (T1D). Children and youth, who are at particular risk for out-of-target glycemia, may have the most to gain from AHCL. However, no randomized controlled trial (RCT) specifically targeting this age group with very high HbA Methods: A prospective, multicenter, parallel-group, open-label RCT, comparing MiniMed™ 780G AHCL to standard care (multiple daily injections or continuous subcutaneous insulin infusion). Eighty participants aged 7-25 years with T1D, a current HbA Conclusion: This study will evaluate the efficacy and safety of AHCL in this population and has the potential to demonstrate that AHCL is the gold standard for children and youth with T1D experiencing out-of-target glucose control and considerable diabetes burden. Trial registration: This trial was prospectively registered with the Australian New Zealand Clinical Trials Registry on 14 November 2022 (ACTRN12622001454763) and the World Health Organization International Clinical Trials Registry Platform (Universal Trial Number U1111-1284-8452). Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-024-01397-4.

Indexed as

Advanced hybrid closed loopArtificial pancreasAutomated insulin deliveryChildren and youthGlycemic controlType 1 diabetes

Identifiers

PMID38932805
PMCPMC11196497

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.